Blood Reviews最新文献_第3页

Low flow: Selecting a limited flow cytometry panel where resources are constrained 低流量：在资源有限的情况下选择有限的流式细胞仪面板。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-03-17 DOI: 10.1016/j.blre.2025.101284

Ailie Ross , Donna Rudd , Joel Wight

引用次数: 0

Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines 弥合从证据到实践的差距：推进新生儿输血。对近期指导方针的叙述性回顾。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-03-08 DOI: 10.1016/j.blre.2025.101282

Rozeta Sokou , Eleni A. Gounari , Andreas G. Tsantes , Daniele Piovani , Stefanos Bonovas , Argirios E. Tsantes , Nicoletta Iacovidou

引用次数: 0

Innovations in red blood cell preservation 红细胞保存方面的创新。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-03-07 DOI: 10.1016/j.blre.2025.101283

Nishaka William , Jason P. Acker

引用次数: 0

BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies BTK抑制剂在B细胞恶性肿瘤中的耐药性：机制和潜在的治疗策略。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-02-20 DOI: 10.1016/j.blre.2025.101273

Xin Liu , Yufan Lin , Qiqi Zhuang , Haoren Deng , Aichun Liu , Jie Sun

引用次数: 0

The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT CAR-T细胞治疗中免疫监测的前景：EBMT细胞治疗和免疫生物学工作组的全面回顾和调查研究。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-02-15 DOI: 10.1016/j.blre.2025.101272

Simona Pagliuca , Florent Malard , Jarl E. Mooyaart , Michael Daskalakis , Ludovic Gabellier , Ibrahim Yakoub-Agha , Ron Ram , Caroline Besley , Edouard Forcade , Vladan Vucinic , Lucía López Corral , Jan Vydra , Bastian von Tresckow , Paula Amat , Persis Amrolia , Peter Vandenberghe , Friedrich Stölzel , Simona Sica , Marie Thérèse Rubio , Jorinde D. Hoogenboom , Annalisa Ruggeri

{"title":"The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT","authors":"Simona Pagliuca , Florent Malard , Jarl E. Mooyaart , Michael Daskalakis , Ludovic Gabellier , Ibrahim Yakoub-Agha , Ron Ram , Caroline Besley , Edouard Forcade , Vladan Vucinic , Lucía López Corral , Jan Vydra , Bastian von Tresckow , Paula Amat , Persis Amrolia , Peter Vandenberghe , Friedrich Stölzel , Simona Sica , Marie Thérèse Rubio , Jorinde D. Hoogenboom , Annalisa Ruggeri","doi":"10.1016/j.blre.2025.101272","DOIUrl":"10.1016/j.blre.2025.101272","url":null,"abstract":"<div><div>Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"71 ","pages":"Article 101272"},"PeriodicalIF":6.9,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies 经典霍奇金淋巴瘤：影响新兴疗法的病理生物学特征。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-30 DOI: 10.1016/j.blre.2025.101271

Mohamed Nazem Alibrahim , Annunziata Gloghini , Antonino Carbone

{"title":"Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies","authors":"Mohamed Nazem Alibrahim , Annunziata Gloghini , Antonino Carbone","doi":"10.1016/j.blre.2025.101271","DOIUrl":"10.1016/j.blre.2025.101271","url":null,"abstract":"<div><div>Classic Hodgkin lymphoma (cHL) is defined by distinctive Hodgkin Reed-Sternberg (HRS) cells, which are CD30+/CD15+ multinucleated tumor cells lacking typical B-cell markers. These cells comprise <5 % of tumor mass but orchestrate an extensive immunosuppressive tumor microenvironment (TME). Classic HL was curable with radiation therapy and multi-agent chemotherapy. Despite high cure rates, treatment-related toxicities remain significant. The goals of multimodality therapy are to achieve a cure while minimizing treatment-associated toxicity. Advances in molecular insights into HRS cells have led to transformative therapies, including checkpoint inhibitors, antibody-drug conjugates like brentuximab vedotin, which have shown remarkable efficacy, especially in relapsed or refractory disease. However, challenges persist due to the heterogeneity of cHL, driven by the complex biology of HRS cells and their surrounding tumor microenvironment. Novel approaches such as single-cell RNA sequencing and circulating tumor DNA profiling provide promising strategies to address these challenges. This review examines the origin, morphology, phenotype, and genetic profiles of HRS cells, highlighting key pathobiological features, including biomarkers and Epstein-Barr Virus involvement. It also explores the biological mechanisms underlying HRS cell survival and evaluates standard and emerging therapies, offering insights into the rationale for novel treatment strategies.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"71 ","pages":"Article 101271"},"PeriodicalIF":6.9,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance PET扫描对滤泡性淋巴瘤组织学转化的检测：诊断表现的系统回顾。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-28 DOI: 10.1016/j.blre.2025.101270

Marc Sorigue , Milos Miljkovic , Pablo Mozas

{"title":"PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance","authors":"Marc Sorigue , Milos Miljkovic , Pablo Mozas","doi":"10.1016/j.blre.2025.101270","DOIUrl":"10.1016/j.blre.2025.101270","url":null,"abstract":"<div><div>The strength of evidence supporting use of PET in the evaluation of suspected histological transformation (HT) of follicular lymphoma (FL) is unknown. We conducted a systematic review of studies reporting the diagnostic performance of ≥1 PET parameters for the detection of HT in patients with known FL. We searched PubMed for any study reporting ≥1 diagnostic performance metrics. Risk of bias was evaluated with the QUADAS2 tool. We included 7 studies encompassing 152 patients with a biopsy showing FL (or indolent non-Hodgkin lymphoma) and 111 with a biopsy confirming HT. Study designs and study populations differed substantially. PET methods were poorly reported and <sup>18</sup>F-FDG dose was highly variable. Most studies were judged to be at high risk of bias in the patient and index test domains of QUADAS2. The diagnostic performance of 5 PET parameters were reported in at least one study but only SUVmax (<em>n</em> = 7) was reported in >2. Median SUVmax ranged from 9.2 to 10.9 in FL/iNHL and from 13.7 to 24.4 in HT. While SUVmax was consistently higher in the HT group, there was considerable overlap between the two groups and significant variability between studies. Area under the ROC curve for SUVmax to distinguish between FL/iNHL and HT ranged from 0.68 to 0.97. Sensitivity and specificity of the proposed cutoffs also varied widely (sensitivity ∼0.6 to 1, specificity ∼0.4 to 1). In conclusion, few studies — mostly small and potentially biased — have addressed this question. Although SUVmax is generally higher in HT than in FL, the diagnostic performance and optimal cutoffs remain unclear. Proposed SUVmax cutoffs should not be used to determine whether a patient has HT or to decide whether a biopsy should be obtained. For now, we encourage physicians to evaluate results of their own practice to devise a prudent workup of suspected.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"71 ","pages":"Article 101270"},"PeriodicalIF":6.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies 慢性淋巴细胞白血病中btki诱导的心血管毒性：风险缓解和管理策略

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-24 DOI: 10.1016/j.blre.2025.101268

Sofija Kozarac , Vojin Vukovic , Michael Fradley , Darko Antic

{"title":"BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies","authors":"Sofija Kozarac , Vojin Vukovic , Michael Fradley , Darko Antic","doi":"10.1016/j.blre.2025.101268","DOIUrl":"10.1016/j.blre.2025.101268","url":null,"abstract":"<div><div>Targeted therapies, consisting of Bruton tyrosine kinase inhibitors (BTKis) or BCL-2 inhibitors, are the mainstay of contemporary treatments for chronic lymphocytic leukemia (CLL). The most common adverse effects (AEs) of BTKis are fatigue, bruising, infection, hematological and cardiovascular AEs. While AEs during treatment are usually mild (grades 1 and 2), grade 3 and 4 AEs have been detected in some patients, necessitating additional medical care and temporary or permanent drug discontinuation. In this review, we analyzed the cardiovascular effects associated with BTKi therapy for CLL and the essential practical aspects of multidisciplinary management of patients who develop cardiovascular toxicity during treatment. We particularly focus on the data and strategies for controlling cardiovascular risks associated with ibrutinib and newer BTKis (acalabrutinib, zanubrutinib and pirtobrutinib), including the development of atrial fibrillation, hypertension, ventricular arrhythmias, sudden death, heart failure, bleeding, and ischemic complications (stroke and myocardial infarction). This review highlights hematological insights underlying cardiotoxicity, an area that has received limited attention in comparison to the predominantly cardiological perspective. This review synthesizes emerging evidence on hematological biomarkers, cardiotoxic mechanisms, and therapeutic interventions, linking hematology and cardiology to enhance understanding and guide comprehensive prevention and management strategies.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"70 ","pages":"Article 101268"},"PeriodicalIF":6.9,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly 放射治疗、克隆造血和血液恶性肿瘤的风险：好的、坏的、丑陋的。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-22 DOI: 10.1016/j.blre.2025.101269

Catherine H. Marshall , Emmanuel S. Antonarakis , Mrinal M. Patnaik

引用次数: 0

Corrigendum to “Impact of transcranial Doppler screening on stroke prevention in children and adolescents with sickle cell disease: A systematic review and meta-analysis” [Blood Reviews (2024) 101253] “经颅多普勒筛查对镰状细胞病儿童和青少年卒中预防的影响：一项系统综述和荟萃分析”[Blood Reviews(2024) 101253]的更正。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-18 DOI: 10.1016/j.blre.2025.101258

Danielle Guy , Robert Bagnall , Rebecca L. Morgan , Ifeoluwa Babatunde , Agathe Nevière , Gabriela Friedrich , Liga Bennetts , Omar Irfan , Isaac Odame

引用次数: 0